Trials / Completed
CompletedNCT04448002
AIM2ACT: A Mobile Health Tool to Help Adolescents Self-Manage Asthma
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 320 (actual)
- Sponsor
- University of Florida · Academic / Other
- Sex
- All
- Age
- 12 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The aim is to test the efficacy of AIM2ACT and long-term maintenance of treatment effects in a fully-powered randomized controlled trial with 160 early adolescents with poorly controlled persistent asthma, ages 12-15 years, and a caregiver
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | AIM2ACT | AIM2ACT is a mobile health tool that is designed to facilitate collaborative asthma management between early adolescents and their caregivers. AIM2ACT contains the following components: 1) ecological momentary assessment to identify personalized strengths and weaknesses in asthma self-management behaviors; 2) collaborative identification and tracking of goals that help early adolescents to become increasingly independent in managing their asthma; and 3) a suite of engaging skills training videos to help dyads understand how to use AIM2ACT and work together to set asthma self-management goals, develop and achieve the goals articulated in a behavioral contract, and engage in problem-solving communication. |
| BEHAVIORAL | mHealth Attention Control Condition | Dyads in the mHealth attention control condition will not receive personalized asthma management feedback, will not be guided through collaborative identification and tracking of asthma self-management goals, and will not have access to skills training videos. Instead, dyads will receive static educational information on their smartphones about behavioral management techniques they can use to target improving asthma self-management. |
Timeline
- Start date
- 2021-04-23
- Primary completion
- 2026-01-22
- Completion
- 2026-01-22
- First posted
- 2020-06-25
- Last updated
- 2026-04-01
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT04448002. Inclusion in this directory is not an endorsement.